白介素-4 受体α 抑制剂治疗特应性疾病。

IL-4Rα Inhibitor for Atopic Disease.

机构信息

Stanford University School of Medicine, Stanford University, Stanford, CA, USA.

出版信息

Cell. 2017 Jul 13;170(2):222. doi: 10.1016/j.cell.2017.06.046.

DOI:10.1016/j.cell.2017.06.046

Abstract

Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Rα subunit of IL-4 and IL-13 receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema). To view this Bench to Bedside, open or download the PDF.

摘要

度普利尤单抗是一种针对白细胞介素-4 受体α亚基（IL-4Rα）的人源化 IgG4 单克隆抗体，可阻断白细胞介素-4（IL-4）和白细胞介素-13（IL-13）受体的信号通路，这两种细胞因子是驱动 2 型炎症反应的关键细胞因子。2017 年 3 月，度普利尤单抗被批准用于治疗特应性皮炎（湿疹）。要查看本《从临床前到临床》，请打开或下载 PDF 版本。